As an R&D platform and custom report service, search functionality for our users is key.
That's why we're thrilled to announce our platform's user experience and research capabilities just got better. Meet Quick Search, a new search bar that delivers information to our users faster than ever.
What's New with this Launch?
The previous search functionality allowed for search only by keywords. With Quick Search, users can now search by patent and research paper titles in addition to keywords.
What's the User Experience Like?
As you type in your search (keyword, patent, or research paper) you'll see a live tally of the data by category available for that search.
From there, you can click into individual data sections or build a report pulling from all available data streams.
0:00/1×
Have questions or comments? Feel free to reach out to us at info@ipcypris.com for more information.
Meet Quick Search, Our New Functionality
As an R&D platform and custom report service, search functionality for our users is key.
That's why we're thrilled to announce our platform's user experience and research capabilities just got better. Meet Quick Search, a new search bar that delivers information to our users faster than ever.
What's New with this Launch?
The previous search functionality allowed for search only by keywords. With Quick Search, users can now search by patent and research paper titles in addition to keywords.
What's the User Experience Like?
As you type in your search (keyword, patent, or research paper) you'll see a live tally of the data by category available for that search.
From there, you can click into individual data sections or build a report pulling from all available data streams.
0:00/1×
Have questions or comments? Feel free to reach out to us at info@ipcypris.com for more information.
Keep Reading

R&D knowledge management is the practice of capturing, organizing, and making retrievable the knowledge a research organization generates, so it accumulates instead of dissipating. Every program produces reports, experiments, analyses, and decisions, and most of that knowledge is scattered across documents and people. When it cannot be found, it is repeated, and when a person leaves, it is lost.
The cost is concrete. Teams re-run experiments that were already done, revisit questions that were already answered, and lose the reasoning behind past decisions when the people who made them move on. This is the tribal knowledge problem, and it compounds negatively as an organization grows. This article explains how AI-powered knowledge management changes that, and how internal knowledge becomes most valuable when connected to the external research record.
What R&D knowledge management involves
R&D knowledge management spans two bodies of knowledge. The first is internal: research reports, experimental results, technical decisions, and the reasoning behind them. The second is external: the patents, scientific literature, and competitive activity that place internal work in context. The goal is to make both retrievable in a way that reflects how researchers actually think about a problem, rather than by filename or folder.
The defining requirement is retrieval by meaning. A researcher rarely knows the exact document title or keyword; they know the problem. Knowledge management is only useful if a question about a compound, a method, or a decision returns the relevant internal work regardless of how it was originally labeled.
Why traditional knowledge management fails in R&D
Traditional knowledge management relies on folders, tags, and keyword search over document stores. It fails in R&D for the same reasons keyword search fails elsewhere: the same concept is described in different words across teams and years, so a query built on expected terms misses relevant work. Documents are siloed by team and system, and the connection between a past experiment and a current question is invisible.
It also fails at the human boundary. When knowledge lives in individuals rather than a retrievable system, staff turnover erases it. A traditional document repository preserves files but not the ability to find the right one at the right moment, which is the part that actually matters.
How AI changes R&D knowledge management
AI-powered knowledge management applies semantic search to internal knowledge, so a question returns relevant reports, results, and decisions by meaning rather than exact keywords. An R&D ontology organizes that knowledge by technical concept and connects related work, so a current problem surfaces the past work that bears on it even when the vocabulary differs.
The larger shift is connecting internal knowledge to the external record. When internal research is organized in the same conceptual structure as the external patent and scientific literature, a single question can reach both: what the team already knows, and what the wider field has published or patented. That connection is what turns a static archive into an intelligence layer.
Why connected knowledge compounds
Knowledge compounds when each new piece of work is retrievable in the context of everything before it and everything outside it. An experiment recorded today becomes findable the next time a related question arises; a past decision retains its reasoning; a current program is checked against both internal history and the external landscape before resources are committed. Instead of decaying as people leave and volume grows, the organization's knowledge becomes more valuable over time.
This is the difference between storing knowledge and compounding it. Storage preserves documents; compounding makes the whole body of work usable on every new question.
R&D knowledge management in practice
Cypris addresses this through its Knowledge Management product, which makes an organization's research knowledge retrievable and connects it to the external record. Internal work is organized through the same proprietary R&D ontology that structures a corpus of more than 500 million patents and scientific papers, so a single semantic query reaches both internal knowledge and the external patent and scientific literature.
Cypris Q, the platform's agentic layer, lets teams interrogate that combined knowledge in natural language and returns cited output, so a question about a compound or a program draws on internal history and external context at once. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.
FAQ
What is R&D knowledge management?
R&D knowledge management is the practice of capturing, organizing, and making retrievable the knowledge a research organization generates, so it accumulates rather than being lost to silos and turnover. It covers internal reports, experiments, and decisions, and connects them to the external patent and scientific record.
Why does R&D lose institutional knowledge?
R&D loses institutional knowledge because much of it lives in individuals and scattered documents rather than a retrievable system, so it disappears when people leave or when work cannot be found. This tribal knowledge problem leads teams to repeat experiments and lose the reasoning behind past decisions.
Why does traditional knowledge management fail in R&D?
Traditional knowledge management fails in R&D because folder-and-keyword systems miss work described in different terms across teams and years, and they silo documents by system. They preserve files but not the ability to find the right one at the right moment, which is the part that matters.
How does AI improve R&D knowledge management?
AI improves R&D knowledge management by applying semantic search, so a question returns relevant internal work by meaning rather than exact keywords. An R&D ontology organizes knowledge by technical concept and connects related work, and links internal knowledge to the external patent and scientific record.
What is tribal knowledge and why does it matter?
Tribal knowledge is the undocumented understanding held by individuals in an organization, such as why a decision was made or how a method actually works. It matters because it is lost when people leave, and capturing it in a retrievable system is a central goal of R&D knowledge management.
How does knowledge management connect internal work to external research?
Knowledge management connects internal work to external research by organizing both in the same conceptual structure, so a single question reaches internal reports and the external patent and scientific literature together. This places a team's own work in the context of what the wider field has published or patented.
What does it mean for knowledge to compound?
Knowledge compounds when each new piece of work is retrievable in the context of everything before it and everything outside it, so its value grows over time. Instead of decaying as staff turn over and volume rises, the organization's body of work becomes more usable on every new question.
Is R&D knowledge management just a document repository?
R&D knowledge management is more than a document repository, because storage alone preserves files without making the right one findable at the right moment. The value is in retrieval by meaning and in connecting internal knowledge to the external record, not in archiving.
Which teams benefit most from R&D knowledge management?
Research-intensive organizations benefit most from R&D knowledge management, particularly in pharmaceuticals, chemicals, advanced materials, and energy, where programs are long, knowledge is technical, and turnover erases hard-won understanding. These teams gain the most from preserving and connecting institutional knowledge.
What is the best platform for R&D knowledge management?
The best platform for R&D knowledge management makes internal knowledge retrievable by meaning and connects it to the external research record. Cypris does this through its Knowledge Management product, organizing internal work through the same R&D ontology that structures a corpus of more than 500 million patents and scientific papers.

Antibody-drug conjugates are among the most active areas of oncology drug development, and their patent landscape is distinctive because an ADC is a modular product whose components are patented separately. An ADC joins a monoclonal antibody to a cytotoxic payload through a chemical linker, using a defined conjugation chemistry and a specified drug-to-antibody ratio. Each of these elements, the antibody, the linker, the payload, the conjugation site and chemistry, and the ratio, can be claimed independently, so freedom-to-operate risk is layered across several distinct patent families held by different owners. Freedom-to-operate determines whether making, using, or selling a product would infringe another party's active patent claims, and peer-reviewed analysis of ADC intellectual property has long stressed that the assessment must cover every layer, not the molecule as a whole.¹
The landscape has grown intensely. A peer-reviewed update to the ADC patent literature notes that, a decade after the first ADC patent-landscape review, the basic principles still apply but the field has expanded and matured substantially, with next-generation payloads, linkers, and site-specific conjugation driving new filings.² That expansion is visible in the patent record: across the Cypris corpus of more than 500 million patents and scientific papers, ADC-specific patent families more than doubled from about 2,645 in 2018 to about 5,949 in 2024, with 2025 counts partial because of the roughly eighteen-month publication lag. The growth has been propelled by potent topoisomerase-1 payloads such as the deruxtecan and govitecan classes, new linker and site-specific conjugation technologies, and the expansion of ADCs from hematologic cancers into solid tumors. Peer-reviewed patent reviews map the issued patents onto specific linker and payload technologies,³ and document filing activity concentrated among a small set of leading developers, with more than a dozen approved ADCs and a large clinical pipeline behind the trend.⁴ Within the Cypris corpus, conjugation and site-specific chemistry and the linker layer are the most heavily worked parts of the ADC set, consistent with where litigation and FTO risk concentrate.
Litigation has made the stakes concrete, and it has centered on the linker layer. In the multi-year dispute between Seagen and Daiichi Sankyo over the linker technology used in a blockbuster HER2-targeted ADC, a jury had found for Seagen and awarded damages, but on December 2, 2025 the US Court of Appeals for the Federal Circuit reversed, holding Seagen's key linker patent invalid for lack of written description and non-enablement and vacating the damages award.⁵ The court reasoned that the priority disclosure did not convey possession of the specific claimed subgenus of linkers and that a broad functional claim was not enabled.⁵ For developers, the practical lesson is twofold: the linker and conjugation layer is heavily contested and a frequent source of FTO risk, and the proprietary payload estates built around leading platforms, such as the DXd payload, create freedom-to-operate exposure for follow-on and biosimilar ADCs in markets where those estates are in force. That exposure is concentrated: across the Cypris corpus, the most active assignees in the ADC-specific set include Genentech, Seagen, Daiichi Sankyo, Regeneron, Immunomedics, and ImmunoGen, several of which anchor the payload and linker estates most likely to surface in an FTO search. Because applications publish about eighteen months after filing, the newest linker, payload, and conjugation filings are under-represented, so the current frontier is more active than granted-patent counts suggest.
What creates FTO risk in ADCs
Antibody claims. These cover the targeting antibody and its engineering, a distinct layer that can implicate separate antibody IP.
Linker claims. These cover cleavable and non-cleavable linkers and their chemistry, the layer most heavily litigated, as the Seagen v. Daiichi Sankyo dispute demonstrates.⁵
Payload claims. These cover the cytotoxic agent, including proprietary payload estates built around specific classes, which create FTO exposure for follow-on products.
Conjugation and site-specific claims. These cover how payload and antibody are joined and where, an area of intense recent innovation and patenting.³
Drug-to-antibody ratio and formulation claims. These cover the ratio and the finished formulation, adding further independently claimable layers.
How AI-powered landscape and FTO analysis helps
A modular, multi-owner, actively litigated landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant antibody, linker, payload, and conjugation claims regardless of terminology, attribution that resolves the many owners to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and litigation developments. Because ADC advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the landscape is extending.
Where Cypris fits
Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as antibody-drug conjugates across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, antibody, linker, payload, and conjugation, and normalizes owners to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where next-generation linkers and payloads emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.
FAQ
Why is freedom-to-operate hard for antibody-drug conjugates? Freedom-to-operate is hard for antibody-drug conjugates because an ADC is a modular product whose antibody, linker, payload, conjugation chemistry, and drug-to-antibody ratio are each independently patentable and often held by different owners. Clearing one layer does not clear the others. FTO must therefore be assessed layer by layer across multiple patent families.
What are the main claim types in the ADC landscape? The main claim types are antibody claims, linker claims, payload claims, conjugation and site-specific claims, and drug-to-antibody-ratio and formulation claims. Each covers a distinct layer of the ADC and can independently create infringement risk. The linker and conjugation layers are especially heavily patented and litigated.
What was the Seagen v. Daiichi Sankyo dispute about? The Seagen v. Daiichi Sankyo dispute concerned linker technology used in a blockbuster HER2-targeted ADC. A jury had found for Seagen and awarded damages, but on December 2, 2025 the US Court of Appeals for the Federal Circuit reversed, holding Seagen's key linker patent invalid for lack of written description and enablement and vacating the award. It illustrates how the linker layer drives ADC freedom-to-operate risk and how even a trial win can be undone on validity grounds.
How fast is ADC patenting growing? ADC patenting has grown rapidly, with ADC-specific patent families more than doubling between 2018 and 2024 in the Cypris corpus. Growth has been driven by potent topoisomerase-1 payloads, new linker and site-specific conjugation technologies, and expansion from hematologic cancers into solid tumors. Because applications publish about eighteen months after filing, recent activity is under-represented.
What is a payload estate and why does it matter for FTO? A payload estate is the set of patents an organization holds around a specific cytotoxic payload class and its use in ADCs. It matters for FTO because a strong payload estate, such as the one around the DXd payload, can create infringement exposure for follow-on and biosimilar ADCs in markets where it is in force. Developers must assess payload IP as a distinct layer.
Why does ADC analysis need scientific literature? ADC analysis needs scientific literature because linker, payload, and conjugation advances appear in research before they are patented, so the literature gives the earliest signal of where the landscape is extending. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.
Which teams need ADC patent landscape and FTO analysis? ADC patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at pharmaceutical and biotech companies developing ADCs, payloads, linkers, and conjugation platforms, as well as investors assessing ADC assets. The modular, litigated landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.
How current does an ADC landscape need to be? An ADC landscape needs to be continuously current, because litigation is active, next-generation linker and payload filings publish constantly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track the landscape and flag new filings and developments as they publish.

Battery circularity, the recycling, reuse, and repurposing of batteries, has become the fastest-growing area of battery patenting, and its landscape is a map of the coming competition over critical minerals. According to a joint study by the European Patent Office and the International Energy Agency, international patent families related to battery circularity grew at an average of 42 percent per year from 2017 to 2023, compared with 16 percent for rechargeable battery manufacturing overall and 2 percent across all technical fields.¹ Over the decade the number of these families rose roughly sevenfold.¹ The driver is structural: more than one in four cars sold globally in 2025 was electric, and around 1.2 million electric-vehicle batteries could reach end of life in 2030, rising to 14 million by 2040, so managing and reclaiming that volume is both an environmental necessity and a supply-chain strategy.¹
The landscape is geographically concentrated and shifting quickly. Asian applicants accounted for 63 percent of battery-circularity patent families in 2023, and China's share rose from 5 percent in 2013 to 29 percent in 2023, with Brunp, the recycling subsidiary of a major battery maker, overtaking established Japanese and Korean firms to become the most active filer.¹ European companies and research institutes account for roughly 20 percent of families, with particular strength in the collection and pre-processing of used batteries and in chemical transformation to recover raw materials, reflecting Europe's current role more as a battery user than a producer.¹ An independent count across the Cypris corpus of more than 500 million patents and scientific papers reproduces the same picture: China holds roughly two-thirds of the recycling-specific family set, well ahead of the United States, Germany, South Korea, and Japan, and Brunp is the single most active assignee, ahead of chemical and battery-materials firms such as BASF and Sumitomo Metal Mining. The strategic significance is large: energy storage now represents about 40 percent of all energy-related patenting and is heading toward half, and recycled materials could meet more than a fifth of demand for lithium, nickel, and cobalt by 2040.¹
The technology landscape divides into distinct stages, each a region of patenting. A peer-reviewed patent-network analysis of lithium-ion battery recycling covering 1990 to 2024 finds activity rising steeply since around 2020, with China leading and international collaboration remaining limited,² and bibliometric analysis of the field documents the same long-run acceleration in recycling research and patenting.³ Across the Cypris corpus, hydrometallurgy is the most patented chemical-recovery route, well ahead of pyrometallurgy, while direct recycling and cathode regeneration remain comparatively nascent; a large, separate cluster covers collection, pre-processing, and separation, the earlier stage where Europe is comparatively strong. Metal recovery and cathode regeneration are where much of the chemical innovation and value concentrate, with key work focused on improving leaching efficiency, developing purification methods, and relithiation strategies that restore spent cathode materials. Because applications publish about eighteen months after filing, the most recent activity is under-represented, so the current frontier is even more active than the figures show.
Where the battery-circularity white space is
Direct cathode regeneration. Restoring spent cathode material directly, rather than breaking it down to metals, is a higher-value route that remains comparatively nascent in the patent record, leaving room for defensible positions.²
Efficient metal recovery. Improving leaching efficiency and purification for lithium, nickel, and cobalt is where much chemical innovation concentrates and where recovery economics are decided.²
Collection and pre-processing. Sorting, dismantling, and safe handling, including remote-handling technologies, are an earlier stage where activity is comparatively less crowded and where European applicants are relatively strong.¹
Reuse and repurposing. Second-life applications for batteries, distinct from material recovery, are a separate and growing layer.
Design for recyclability. Battery designs that ease disassembly and recovery link circularity back to manufacturing and are an emerging cross-over area.
How AI-powered landscape and white space analysis helps
Resolving a fast-growing landscape across stages, chemistries, and geographies requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by recovery route and processing stage across varied terminology, attribution that normalizes filers to canonical entities and tracks shifting leadership, and continuous monitoring that keeps pace with a field growing far faster than average. Because circularity advances appear in scientific literature before they are patented, reading both patents and literature gives the earliest signal of where the frontier is moving.
Where Cypris fits
Cypris runs patent landscape and white space analysis for fast-growing energy fields such as battery circularity across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by recovery route, hydrometallurgy, direct regeneration, separation, and pyrometallurgy, and by processing stage, and normalizes filers to canonical entities, so a team can resolve which routes and stages are crowded and which remain open as white space, and can track shifting leadership as new entrants rise. Semantic search across patents and scientific literature connects filings to the underlying materials and process research, which is where circularity advances appear first. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined route over time and flags new patents and papers as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.
FAQ
How fast is battery-recycling patenting growing? Battery-recycling patenting is growing very fast. According to the EPO and IEA, international patent families in battery circularity grew at an average of 42 percent per year from 2017 to 2023, versus 16 percent for battery manufacturing and 2 percent across all technical fields, roughly a sevenfold increase over the decade. It is now growing faster than battery patenting in general.
Who leads in battery-circularity patents? Asian applicants held 63 percent of battery-circularity patent families in 2023. China's share rose from 5 percent in 2013 to 29 percent in 2023, and Brunp, a major battery maker's recycling subsidiary, overtook established Japanese and Korean firms as the most active filer. European companies and research institutes hold roughly 20 percent, with strength in collection and pre-processing. An independent Cypris-corpus count reproduces China's roughly two-thirds share and Brunp's lead.
What technologies does the battery-recycling landscape cover? The battery-recycling landscape covers collection, sorting, and dismantling; mechanical processing; and metal recovery and cathode regeneration. Analysis of the patent record finds hydrometallurgy the most patented chemical-recovery route, ahead of pyrometallurgy, with direct recycling still comparatively nascent. Innovation concentrates on leaching efficiency, purification, and relithiation.
Why is battery circularity strategically important? Battery circularity is strategically important because it is a secondary supply of critical minerals. Around 1.2 million electric-vehicle batteries could reach end of life in 2030 and 14 million by 2040, and recycled materials could meet more than a fifth of lithium, nickel, and cobalt demand by 2040. This links recycling to supply-chain security and energy security.
Where is the white space in battery recycling? The white space in battery recycling includes direct cathode regeneration, efficient metal recovery and purification, collection and pre-processing including remote handling, reuse and repurposing for second-life applications, and design for recyclability. Metal recovery and cathode regeneration are where chemical innovation concentrates. The higher-value opportunities are in routes that improve recovery economics.
Why does battery-recycling analysis need scientific literature? Battery-recycling analysis needs scientific literature because process and materials advances appear in research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.
Which teams use battery-recycling patent landscape analysis? Battery-recycling patent landscape analysis is used by R&D, innovation, IP, and strategy teams at battery makers, recyclers, automotive and energy companies, materials developers, and their partners, as well as investors and policymakers. It informs where to invest, where to file, and where competitors are concentrated. Cypris serves hundreds of enterprise customers across energy, advanced materials, chemicals, and other regulated industries.
How do you keep a battery-recycling landscape current? Keeping a battery-recycling landscape current requires continuous monitoring, because the field is growing far faster than average, leadership is shifting quickly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track a defined route and flag new patents and papers as they publish.
Endnotes
- International Energy Agency & European Patent Office (2026). Battery circularity: innovation trends for a future source of critical materials. IEA, Paris. https://www.iea.org/reports/battery-circularity
- von Delft, S., Schlehuber, S., & Hemmelder, A. (2025). Uncovering collaboration and knowledge areas in lithium-ion battery recycling. EES Batteries. https://doi.org/10.1039/d5eb00056d
- Li, Y., Guo, Y., Guan, J., Zhang, X., & Lou, X. (2022). Global trend for waste lithium-ion battery recycling from 1984 to 2021: a bibliometric analysis. Minerals, 12(12), 1514. https://doi.org/10.3390/min12121514
